The Emerging Role ofApoptosis in Treating Metastatic Cells
One of the characteristics of cancer is metastasis, the ability of a cell to break free from the surrounding extracellular matrix, migrate, and invade other organs. The most effective cancer therapeutic is targeted at killing these invasive cells rather than inducing cell senescence (Meng et al., 2006) . Successful cancer therapeutics cause neoplastic cells to undergo apoptosis, ultimately preventing both proliferation and migration of cancer cells. Apoptosis is an essential part of cell development. In order for humans to develop fingers and toes or to form new synapses in the brain, requires the removal of extraneous cells. Apoptosis is also a way to remove cells that threaten the structural organization which allows multicellular organisms to thrive (Kerr et al., 1972 ).
The Interaction of Cell Surface Receptors and Signaling Systems They Affect
In a homeostatic environment cells, within a multicellular organism have extracellular and intracellular signals that convey cell boundaries and are the basis for the formation of tissues. Cells interact with the extracellular matrix (ECM) through the binding of ECM adhesion molecules and cell surface receptors, one of which is a family of receptors known as integrins. Integrins are transmembrane receptors composed of a combination of different alpha and beta subunits. Depending upon the combination of the alpha and beta subunit, an integrin bound to insoluble proteins (fribonectin and vitronectin), soluble proteins (disintegrins), or neighboring cells, transfers a signal that induces the cell to migrate, proliferate, or undergo apoptosis. Recent cancer research has capitalized on the role of integrins in the signaling of apoptosis and focused on finding antagonist molecules that will induce this signal (Aguzzi et al., 2004) .
Among these molecules are disintegrins, a low molecular weight, snake venom proteins that are released as part of a larger protein, matrix metolloprotease, known as snake venom metalloprotease (SVMP), or after proteolytic cleavage as a monomer or dimer (Ramos et al., 2008) . Disintegrins are non-enzymatic molecules, with a cysteine rich portion, and a tripeptide (arginine/glycine/aspartic acid) called the RGD-loop. In its tertiary arrangement the cysteine rich portion forms disulfide bonds creating a hairpin loop, exposing the RGD tripeptide in the loop region (McLane et al., 2004) . The RGDloop when bound to an integrin provides potency of signal and the amino acids immediately flanking the RGD tripeptide, in the N-terminal and C-terminal regions, provide specificity and affinity for a particular integrin (Kini, 1998; Rahman et al., 1998) .
Other tripeptide binding motifs include KGD, MVD, MLD, VGD, ECD, and MDG (Lu et al., 2006) .
RGD-Loop and Disintegrin Specificity
The binding specificity and affinity of integrins has been attributed to the amino acids flanking the RGD-loop of disintegrins (Kini and Evans, 1995a; Kini and Evans, 1995b; Rahman et al., 1998) . In experiments where Kini and Evans (1995) replaced two amino acids, one in the N-terminal and one in the C-terminal region adjacent to the RGDloop of the peptide IARGDMNA, with a Pro residue, converting it to IPRGDMP, they found that the antiplatelet activity increased by up to 13-fold. Rahman et al. (1998) found that by replacing the N-terminal and C-terminal amino acids flanking the RGDloop of elagantin, changing the 50 th amino acid from Ala to Pro, and the 54 th amino acid from Met to Asn, they were able to affect inhibitory potency of elagantin (Figure 1 ). To this end, the mojastin disintegrin was mutated at the 54 th and 55 th amino acids (the two amino acids immediately C-terminal to the RGD tripeptide) to mimic those of echistatin (RGDDM) and rhodostomin (RGDMP). In vivo studies have shown the induction of apoptotic activity of endothelial cells after exposure to accutin, agkisrin-s, echistatin, and rhodostomin (Brassard et al., 1999; Ren et al., 2006; Wu et al., 2003; Yeh et al., 1998) .
These disintegrins bind to a v P3 and asPi integrin receptors phosphorylating FAK and inducing caspase-3 activation of apoptosis (Alimenti et al., 2004; Wierzbicka-Patynowski et al., 1999) . Studies using recombinant disintegrins are aimed at increasing their binding specificity to integrins and also to improve their bioavailability (Eble and Haier, 2006) .
Mojastin, a disintegrin found in the Crotalus scutulatus scutulatus venom, has 70 amino acids with a molecular weight of 7 kDa. Mojastin was previously shown to inhibit platelet aggregation in whole human blood at IC50 of 13.8 nM. However, mojastin was ineffective at inhibiting T24 cells, which exhibits the receptors a v p3 and as Pi (Sanchez et al., 2006) . The 0^3 and a$\ integrin receptors, have been linked to apoptosis, and bind both echistastin and rohodostomin. In order to alter mojastin's specificity the amino acids at the 54 th and 55 th amino acid were changed (Figure 2 ).
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Elegantin In this study we used mutant mojastin constructs provided by the Soto lab, to express recombinant fusion proteins and test their ability to induce apoptosis.
1.4
The specific aims of this study were to:
1. Express and purify recombinant GST-MO J wild-type and mutants.
2. Determine whether changing the 54 th and 55 th amino acid residues, Qmmediately C-terminal to the RGD tripeptide, induced apoptosis in HUVEC cells. (Wyllie, 1992) .
Review of Literature
Apoptosis is critical for the development and structural organization of multicellular organisms. This observation is best exemplified in the embryonic development of Caenorhabditis elegans.
A Simple Model of the Apoptosis Signaling Cascade
In the development of hermaphroditic C. elegans, 131 of the 1090 cells had a predetermined time of death indicating that cell disposal was the result of genetic control (Peter et al., 1997) . In C. elegans, ced-3 and ced-4 are proapoptotic genes and ced-9 negatively regulates apoptosis. CED-3 is a cysteine protease and initiates apoptosis, when cleaved by CED-4. CED-9 binds to CED-4, which is in turn bound to the CED-3 zymogen, to form a complex that represses the proteolytic activity of CED-4. Binding of CED-9 with EGL-1 displaces CED-4, releasing CED-4, and enabling it to activate the CED-3 zymogen, thus initiating apoptosis (Borner, 2003; Hengartner and Bryant, 2000; Kaufmann and Hengartner, 2001; Peter et al., 1997; Wyllie, 1997) . The caspases, Apaf-1, and Bcl-2 are mammalian homologues of CED-3, 4, and 9, respectively. However, the apoptotic signaling mechanism in mammals differs from those of C. elegans.
Starting from the Top: Extrinsic and Intrinsic Signaling
Although the mammalian signaling cascade for apoptosis is much more complicated, the homologues of CED-3,4, and 9, in mammals, still share the same general roles. Similar to CED-3, caspases are the initiators and effectors of apoptosis. DNA damage, oxidative stress, starvation, or chemotherapeutics (Borner, 2003) cause the releases cytochrome-c from the mitochondria into the cytoplasm, initiating the intrinsic pathway. Cytochrome-c binding in the presence of ATP causes a conformational change to the apoptotic protease activating factor-1 (Apaf-1), increasing its affinity for procaspase-9. Binding of the caspase recruitment domain (CARD) portion of Apaf-1 to the CARD of procaspase-9, results in the formation of a complex called the apoptosome. Activated caspase-9, within the apoptosome, can then act on caspase-3 and 7 leading toward apoptosis.
Bcl-2 Family: Regulating Apoptosis
As mentioned above, the Bcl-2 family of proteins in mammals is homologous to CED-9 of C. elegans. Proteins in the Bcl-2 family share one or more of four common Bcl-2 homology domains (BH1-BH4) and can be grouped according to their ability to either promote apoptosis or cell survival. Antiapoptotic Bcl-2 members include Bcl-2, Bcl-B, Bcl-Xi, Bcl-W, Bfl-l/Al, and Mcl-1, while proapoptotic Bcl-2 family members can be further divided into the Bax-family (Bax, Bak, and Bok/Mtd) and the BH3 only family (Bid, Bad, Bmf, Hrk/DP5, Noxa, and Puma) (Vermeulen et al., 2005) . Though the exact mechanism of regulation by the Bcl-2 family members is still under debate, the role of Bcl-2 as a regulator of apoptosis is clear.
Under homeostatic conditions Bax exists in the cytosol, and Bak in the mitochondria in their monomeric form. However, under stimuli such as DNA damage, starvation, or cell detachment, BH3-only member proteins are upregulated causing the tranfers of the death signal to the mitochondria. Bax and Bak are sequestered to the outer mitochondrial membrane where they homodimerize. It is unclear whether Bax/Bak, form membrane channels or whether they facilitate the opening of voltage gated channels, but their presence causes the permeabilization of the outer mitochondrial membrane. This results in the release of cytochrome-c into the cytoplasm (Borner, 2003; Chowdhury et al., 2006; Vermeulen et al., 2005) and the onset of the intrinsic signaling pathway of apoptosis. Antiapoptotic Bcl-2 family members such as Bcl-2 and Bcl-X] are believed to regulate proapoptotic signals by maintaining outer mitochondria membrane integrity, though the mechanism has yet to be determined.
Integrin Signaling and the Consequences of Extracellular Matrix Detachment
In tissues, cells attach themselves to the extracellular matrix through receptor binding of integrins with cell adhesion molecules. The specific binding of integrins (avP3, and a5pi) leads to clustering of similar integrins on the cell membrane surface.
This clustering recruits focal adhesion molecules such as talin, viniculin, Src, and FAK (Matter and Ruoslahti, 2001) . FAK, focal adhesion kinase, causes phosphorylation of phoshotidyl-inositol-1, 3, 4-diphosphate (PIP2) to form phoshotidyl-inositol-1, 3, 4, 5-triphosphate (PIP3) to act on PKB/Akt molecules which inhibit the activity of proapoptotic Bcl-2 family members such as Bad, Bim, and Bax, thus suppressing apoptosis. In the absence of this inhibition by PKB/Akt, due to detachment from the substratum or antagonistic binding of integrin receptors, the proapoptotic molecules translocate to the outer mitochondrial membrane, initiating the intrinsic apoptosis signaling pathway (Barja-Fidalgo et al., 2005; Bouchard et al., 2008; Grossmann, 2002) .
Detection of Apoptosis
Annexin V binds with high affinity and specificity to phosphotidyl serine a membrane phospholipid. In viable cells phophotidyl serine faces the cytosol. During the early stages of apoptosis phosphotidyl serine flips and is exposed to the extracellular matrix (Vermes and Haanen, 1994) . However the integrity of the membrane is maintained, differentiating these apoptotic cells from necrotic cells, which loose membrane integrity and exhibit membrane leakage. Using Annexin V attached to fluorescein isothiocyannate (FITC), a green fluorescence molecule, and a counter stain propidium iodide, a red fluorescence molecule, the number of apoptotic cells in a population may be quantified.
Methods

Transformation of Escherichia coli
PGEX-KG vectors containing the mutated mojastin constructs, developed by researchers in the Soto lab, were added to 100 ul of E.coli BL21-GOLD (Strategene) or NEB-DH5a (New England BioSciences) competent cells and the transformation was carried out according to the manufacturer's instructions. The cells were left to incubate for 30 min on ice, while SOC medium (Stratagene), was preheated in a 42°C waterbath.
The transformation reaction was heat-pulsed at 42°C for 20 s and incubated on ice. After 2 min, 900 ul of warmed SOC medium was added to the reaction. The transformation reaction was then placed on a shaker and left to incubate at 37°C, 250 rpm for 1 h.
Finally 20 ul of the tranformant was streaked on Lauria-Bertani agar (Fisher) with ampicillin plates and left to incubate at 37°C overnight.
Fusion Protein Expression
Eight colonies were cultured in 200 ml of 2x Yeast-Tryptophan (QBiogene) or Lauria-Bertani (LB) broth in the presence or absence of 10 ug/ml ampicillin. The culture was grown to an OD600 of 0.6-0.8 with vigorous agitation, 225 rpm, at 37°C. GST-MOJ was induced by adding 1 mM of isopropyl P-D-thioglalactoside (Amersham Biosciences) and left to incubate for an additional 2 h. The culture was then transferred to four 50 ml centrifuge tubes and centrifuged at 700x G for 10 min to obtain the pellet. The supernatant was discarded and the pellet was suspended in lx PBS (Gibco).
Lysis and Purification of GST-MO J
Cells were lysed using a sonicator, 20 bursts followed by 20 s on ice. The supernatant was retained after centrifugation for 10 min at 700x G and applied to a 1 ml GSTrap column (GE Biosciences) at 0.2-1 ml/min. The column was washed 5 ml with lx PBS and eluted with 5 ml of reduced glutathione. Protein concentrations were determined using the Bradford assay.
Molecular Weight Determination of GST-MO J using SDS-PAGE Gels
Proteins samples were mixed with lx Laemmli Sample Buffer (BioRad) and boiled at 95°C for 5 min. The samples were cooled at room temperature and 40 ul was added to a NuPAGE 4-12 %, Bis-Tris gel (Invitrogen). The gel ran at 120 mA for 40 min in MES Buffer (Invitrogen). The gel was then stained with Coomassie Brilliant Blue (Sigma).
Culturing HUVEC Cells
HUVEC were a product of Lonza (C2517A) and cultured in 25 cm 2 flasks with endothelial cell basal medium (EMB-2 Basal Medium, CC3156) supplemented with:
BBE, 2 ml; hEGF, 0.5 ml; Hydrocortisone, 0.5 ml; FBS, 10 ml; GA-1000, 0.5 ml. They were incubated at 37°C with 5% CO2. The cells were subcultured once they reached 80%
confluency. The process involved aspirating used media, washing with 5 ml of PBS, and detaching using 0.05% tryspin EDTA (Invitrogen). The action of trypsin was neutralized with the complete culture media containing 2% bovine serum albumin. Cells were then split 1:2 and transferred to new 25 cm 2 flasks.
Apoptosis Detection
HUVEC cells were cultured to 80% confluency in a 75 cm tissue culture flask The cells were spun down and washed two times with cold PBS. Then they were resuspended in 1 ml of lx PBS. Afterward, 100 ul was removed and exposed to 5 ul each of Annexin V-FITC and Propidium Iodide (BD Biosciences). The reaction was left at room temperature for 15 min and analyzed using the FACSCalibur after 400 ul of lx binding buffer was added. Statistical analysis of the percent apoptotic cell population, using paired t-tests, was performed using InStat (GraphPad).
Hoechst 33258 Staining
HUVEC cells were cultured and collected as above and seeded 2.5 x 10 5 cells per slide well chamber (Nalgene). The cells were then fixed in 3% paraformaldehyde, then set in 100% cold methanol and stained with 10 ug/ml of Hoechst 33258 (Invitrogen).
Results
Optimization of Culturing Conditions for Fusion Protein Expression
The GST fusion protein expression in the E. coli NEB-DH5a strain was compared to those of the BL21 strain (Figure 3 
Detection of Purified GST-MOJ Fusion Protein Using SDS-PAGE
After optimization of culture conditions, the GST-MOJ fusion proteins were expressed and purified using 1ml GSTrap affinity columns. SDS-PAGE was used to verify the purification of the GST fusion proteins from cell lysate. It was also determined that expression system E. coli was adequate for the production of GST-MOJ recombinants ( Figure 4 ). As seen in lane 4, the pGEX-KG vector, without the mojastin insert, produced a band at 29kDa, the predicted size of the GST protein, whereas pGEX-KG with the mojastin insert produced a band at the predicted size of 34 kDa (lane 6).
Once it was established that the GST-MOJ fusion proteins were produced using this approach, the GST-MOJWP, NN, DM, and MP fusions proteins ( Figure 5 ) were expressed and purified (lanes 4, 6, and 8 in panel A; lane 3 in panel B). Some of the samples also included GST by itself (blue arrow heads). This is the result of randomly selecting eight E. coli colonies, after transformation of BL21 cells, for culture. Cell lysates were also included in lanes 3,5, and 7 of panel A and lane 2 of panel B.
Optimization of Annexin V-FITC Detection of Apoptosis using FACSCalibur
The ability to detect apoptosis, in an Annexin-V-FITC assay, was determined using camptothecin, a known inducer of apoptosis in HUVEC cells (Simak et al., 2002) . apoptosis in Pi cells (Alimenti et al., 2004) , was also tested as a positive control for apoptosis ( Figure 7) . Unfortunately, the apoptotic responses to echistatin at concentrations: 10 uM (2.00%), 20 uM (1.72%), 50 uM (2.98%), and 100 uM (2.88%);
were similar to those of untreated HUVEC cells. Echistatin was chosen to be the other positive control, because it has been shown to induce apoptosis in endothelial cells and it was commercially available. Unfortunately, the echistatin purchased from Sigma showed no apoptotic activity. The manufacturers of echistatin were not forthcoming about the methods of echistatin production and Sigma, the distributing company, did not have any activity data on the disintegrin.
HUVEC cells were exposed to GST, as a negative control for apoptosis ( Figure   8 ). There was no increase in apoptotic activity at concentrations luM (1.24%) and 10 uM(1.59%).
Apoptosis Detection in HUVEC Cells after Exposure to GST-MO J Fusion Proteins
The mojastin disintegrin (RGDWN) has been shown to inhibit ADP-induced platelet aggregation at IC50 13.8 nM (Sanchez et al., 2006) . In this study wild-type Figure 8. GST was tested at 1, 10 and 15 uM, for its affect on the viability of HUVEC cells. There was no change in the early stage apoptotic population (lower right quadrant; panels C, D, and E). However the late stage apoptotic and necrotic cell population did increase in a dose dependent manner; 5.77% at 1 uM (panel C) and 9.72% at 10 uM (panel D). Figure 9 . The apoptotic affect of 5 uM wild-type and mutant mojastin recombinant fusion proteins were tested on HUVEC cells. At 5 uM the percent of early stage apoptotic cells for each of the mutants and the wild-type were the similar as the untreated cells (1.41% ± 0.3). Statistical analysis using a paired t-test showed that the means were not significantly different for the wild-type and mutant mojastin recombinant fusion proteins as compared with the untreated sample (P > 0.05). This data reflects measurements taken from three different experiments. The bars represent ± SD. Figure 10 . Apoptosis as characterized by nuclear condensed fragments were visualized using 10 ug/ml Hoechst 33258. HUVEC cells exposed to 5 uM GST-MOJWN and GST-MOJNN did not show an increase in nuclear condensation as compared with cells exposed to 2.5uM camptothecin (white arrows).
Conclusion
Disintegrins as a Cancer Therapeutic
Integrin binding of adhesion molecules in the extracellular matrix has been shown to induce signaling pathways that on the one hand result in cell migration and proliferation, while also suppressing signaling pathways that cause cells to undergo self destruction (Barja-Fidalgo et al., 2005; Zhang et al., 1995) . Dysfunction in these signaling pathways causes tumor progression and metastasis. Thus it has been the aim of 
Protein Modeling: Predicting the Apoptosis Inducing Structure of Disintegrins
Researchers in the Soto lab used site directed mutagenesis to change the 54 l and/or 55 th amino acid of the mojastin disintegrin to create ten mutants. In order to predict the activity of these mutants, three dimensional models were constructed using homology modeling. In this model a high resolution x-ray structure of trimestatin (Fujii et al., 2003) was used as a template for the disintegrin protein, due to the lack of structural information available for mojastin. Trimestatin was chosen because it shared the highest sequence similarity to mojastin (81.7%), compared with any other medium length disintegrin. The mojastin sequence was aligned using trimestatin as the template by the program MODELLER. This produced five possible three dimensional models for mojastin. These models were analyzed using PROCHECK, a program that generates
Ramachandran plots depicting the best stereochemistry for each of the models. The models chosen had 91% of their residues in favorable regions. This confirmed the reliability and stereochemical accuracy of the models produced. CHIMERA was then used to create a surface model which provided the best indicator of overall structure visually.
Using the three-dimensional structures created in this way researchers in the Soto lab were able to pick four mutants, from the ten, which were most likely to affect the induction of apoptosis. Two of the mutants contained the same 54 th and 55 th amino acids as echistatin (RGDDM) and rhodostomin (RGDMP). Echistatin (10 ug/ml) elicited an apoptotic response when exposed to GD25 cells (Alimenti et al., 2004) and 4 ug/ml of rhodostomin induced apoptosis in HUVEC cells (Wu et al., 2003) . Two others mutants (NN and WP) were chosen for their structural similarity in the C-terminal region to MP because the models showed that changes in the 54 th and 55 th amino acids affect a conformational change in the C-terminal domain of disintegrins. Thus these four mutants along with wild-type mojastin ( Figure 11 ) were chosen to be expressed as GST fusion proteins and assayed for their ability to induce apoptosis. Figure 11 . Surface models for mojastin and mutant sequences. Mojastin (WN); the two mutants with sequence similarity to rhodostomin (DM) and echistatin (MP); and the two mutants structurally similar to echistatin (NN and WP) are presented.
Here the RGD-loop is shown in red and the C-terminus is shown in green. These models were created using MODELLER and visualized using CHIMERA. Each model was analyzed using PROCHECK to determine the most probable stereochemistry.
Wild-Type and Mutant Recombinant Fusion Proteins: Inability to Induce Apoptosis
Although, mojastin 1 and 2 inhibit platelet aggregation, the recombinant mojastin did not induce apoptosis in HUVEC cells, which is not surprising since mojastin did not inhibit T24 cells from binding fibronectin (Sanchez et al., 2006) , the adhesion molecule bound by integrin receptors a$\ (Berman et al., 2003) . However, it is surprising that GST-MOJDM and GST-MOJMP did not induce apoptosis in HUVEC cells. There are three possible explanations for my findings. Either the fusion proteins produced in this study were misfolded, apoptosis induced cell death due to exposure to disintegrins may be cell specific, or the RGD-loop recognition sequence produced was insufficient for a v P3
and (X5P1 integrin signaling of apoptosis.
Researchers have found that disintegrins produced E. coli have biological activity.
Recombinant elegantin (Rahman et al., 1998) and rhodostomin (Chang et al., 1993) ,
expressed by E. coli as glutathione-S-transferase fusion proteins, retained their structural morphology and biological activity. GST-Elegantin had the same inhibitory potency (IC50 0.3 uM) as the purified toxin in ADP-induced platelet aggregation of platelet rich plasma (Rahman et al., 1998) . Change et al. (1993) rhodostomin has been shown to induce apoptosis in HUVEC cells (Wu et al., 2003) .
Thus some other factor must be influencing the lack in apoptotic activity of GST-
MOJMP.
Since inhibition studies with kristin and dendroaspin, two disintegrins with the same sequence (PRGDMP), showed that they bound with equal avidity to am,P3, it was surprising that the mutants GST-MOJDM and GST-MOJMP with C-terminal residues adjacent to the RGD-loop similar to echistatin (RGDDM) and rhodostomin (RGDMP)
did not induce apoptosis (Rahman et al., 1995) . Kristin and dendroaspin also competed with each other for the same receptor binding site on ocm^ integrins (Rahman et al., 1995) , suggesting that the target for the two disintegrins is the same. Exploration of the N-terminal residues adjacent to the RGD-loop may produce a mojastin mutant recombinant fusion protein that can induce apoptosis in endothelial cells.
Studies done with recombinant echistatin point out the C-terminal domain of the disintegrin to be a contributing factor in a 5 Pi binding (Wierzbicka-Patynowski et al., 1999) . In their study Wierzbicka-Paynowski et al. (1999) examined at conformation changes in the integrin model due to ligand binding using antibodies, called anti-ligandinduced binding site (LIBS) antibodies, to the new binding site. They substituted the Cterminal sequence of eristostatin (WNG) with those of echistatin (HKGPAT) and found that inhibitory potency of the hybrid increase was over 4-fold greater than that of the wild-type. This suggests that C-terminal region of the mojastin should be considered when producing mutant mojastin recombinants to affect apoptosis.
The amino acids N-terminal to the RGD-loop are PARGDDM for echistatin and IPRGDMP for rhodostomin. Binding studies done with elegantin showed that replacement of the Pro residue, N-terminal to the RGD-loop, with Ala produced peptides that bound with greater avidity to (X5P1, emphasizing that not only does the C-terminal residues flanking the RGD-loop, contribute to the binding specificity of integrins, but the residues N-terminal residues to the RGD-loop contribute as well (Rahman et al., 1995) .
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